The Society of Chemical Manufacturers and Affiliates issued a statement to support a recently introduced bill that it says will allow the federal government to more effectively deal with market-access barriers.
The Society of Chemical Manufacturers and Affiliates (SOCMA) issued a statement to support a recently introduced bill intended to help the federal government deal with market-access barriers more effectively. The bill, HR 3112, the Trade Law Enforcement Act, was introduced by Rep. Michael Turner (R-OH) on Oct. 6, 2011. The bill would formalize the process by which the Office of the United States Trade Representative (USTR) acts on market-access barriers that are deemed unlawful under US trade agreements.
“This bill elevates a process already in place for companies to report the unfair practices they are experiencing for investigation,” said SOCMA in a Nov. 3, 2011, press statement. “Formalizing the process allows companies to understand the resources that exist within the government, which often they do not know exist. In a time when businesses are looking more at new opportunities to export abroad to growing markets, having a resource such as this to ensure that companies can take full advantage of opportunities and agreements we have in place is extremely important.”
Under current law, the USTR has the ability to respond to various trade practices deemed unfair, including market-access problems caused by nontariff barriers. SOCMA says that while US manufacturers can petition the USTR to take action, they seldom do, partly because of the cost of compiling an adequate petition and the uncertainty of getting timely relief.
SOCMA is urging other members of Congress to show their support for the legislation. SOCMA is the US-based trade association representing custom and batch manufacturers, including producers of fine chemicals, pharmaceutical intermediates, and APIs.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.